GlassScriptPhysician profile
Gerald Paul Norris
NPI 1619941838
$2,898.93
in general payments reported to CMS, 2019-2025
25 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $231 · 2021: $172 · 2022: $472 · 2023: $695 · 2024: $620 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $629.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $466.15 | 2021-2025 | |
| Lilly USA, LLC | $438.14 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $409.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.84 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $140.61 | 2023-2025 | |
| Glaxosmithkline, LLC. | $102.87 | 2022-2025 | Shingrix, Arexvy |
| Amgen INC. | $77.08 | 2020-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $69.94 | 2019-2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $67.10 | 2020-2025 | Veozah |
| Dexcom, INC. | $38.62 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $36.79 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $35.88 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $33.60 | 2025 | Cologuard Collection Kit |
| Endogastric Solutions, INC | $30.00 | 2024 | Esophyx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $23.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.51 | 2024 | Eliquis |
| Horizon Therapeutics Plc | $20.58 | 2023 | Krystexxa |
| Abbott Laboratories | $19.43 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.96 | 2024 | Gvoke Hypopen |
| Pulmonx Corporation | $16.26 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.92 | 2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $13.79 | 2023 | Gemtesa |
| Gilead Sciences, INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.